CO6630141A2 - Método para reducir la presión intraocular en sere humanos empleando n6-ciclopentiladenosina (cpa) derivados de cpa o profármacos de estos - Google Patents

Método para reducir la presión intraocular en sere humanos empleando n6-ciclopentiladenosina (cpa) derivados de cpa o profármacos de estos

Info

Publication number
CO6630141A2
CO6630141A2 CO12183283A CO12183283A CO6630141A2 CO 6630141 A2 CO6630141 A2 CO 6630141A2 CO 12183283 A CO12183283 A CO 12183283A CO 12183283 A CO12183283 A CO 12183283A CO 6630141 A2 CO6630141 A2 CO 6630141A2
Authority
CO
Colombia
Prior art keywords
cpa
prodrugs
cyclopentyladenosine
humans
intraocular pressure
Prior art date
Application number
CO12183283A
Other languages
English (en)
Inventor
Norman N Kim
William K Mcvicar
Thomas Mccauley
Prakash G Jagtap
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CO6630141A2 publication Critical patent/CO6630141A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporciona un método para reducir la presión intraocular (PIO) en seres humanos empleando N-ciclopentiladenosina (CPA), derivados o profármacos de CPA, o formulaciones de CPA con una permeabilidad de la córnea mejorada. En una realización, la invención se refiere a derivados o profármacos de CPA que pueden penetrar la córnea. En otra realización, la invención se refiere a los usos de ciertos compuestos en sujetos humanos para reducir y/o controlar PIO elevadas o que fluctúan de forma anómala en el tratamiento del glaucoma o la hipertensión ocular (HTO)
CO12183283A 2010-03-26 2012-10-17 Método para reducir la presión intraocular en sere humanos empleando n6-ciclopentiladenosina (cpa) derivados de cpa o profármacos de estos CO6630141A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31810510P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
CO6630141A2 true CO6630141A2 (es) 2013-03-01

Family

ID=44673656

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12183283A CO6630141A2 (es) 2010-03-26 2012-10-17 Método para reducir la presión intraocular en sere humanos empleando n6-ciclopentiladenosina (cpa) derivados de cpa o profármacos de estos

Country Status (15)

Country Link
US (4) US8476247B2 (es)
EP (1) EP2569325A4 (es)
JP (2) JP2013523739A (es)
KR (1) KR20130029050A (es)
CN (1) CN102933593A (es)
AU (1) AU2011230580A1 (es)
BR (1) BR112012023749A2 (es)
CA (1) CA2792266A1 (es)
CL (1) CL2012002613A1 (es)
CO (1) CO6630141A2 (es)
EA (1) EA201290958A1 (es)
MX (1) MX2012010724A (es)
SG (1) SG184221A1 (es)
WO (1) WO2011119969A1 (es)
ZA (1) ZA201207090B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2613698T3 (es) * 2010-01-11 2017-05-25 Inotek Pharmaceuticals Corporation Combinación, kit y método de reducción de la presión intraocular
SG184221A1 (en) * 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
KR20140128974A (ko) 2012-01-26 2014-11-06 이노텍 파마슈티컬스 코포레이션 ((2r,3s,4r,5r)-5-(6-(시클로펜틸아미노)-9h-퓨린-9-일)-3,4-디히드록시테트라히드로푸란-2-일) 메틸 니트레이트의 무수 다형체들 및 이들의 제조 방법들
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
BR112017011891A2 (pt) * 2014-12-03 2018-07-03 Inotek Pharmaceuticals Corp métodos de prevenção, redução ou tratamento de degeneração macular

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (es) 1970-12-28 1974-09-25
CH563405A5 (es) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP1224935A3 (en) 1988-09-06 2003-03-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (es) 1992-05-14 1992-05-14 Novo Nordisk As
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
EP0991414A4 (en) 1997-05-09 2002-10-02 Univ Pennsylvania METHODS FOR REDUCING CARDIAC ISCHEMIC LESION BY ADMINISTRATION OF ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS AND RELATED COMPOSITIONS
AU9596698A (en) 1997-10-15 1999-05-03 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6528516B1 (en) 1998-07-16 2003-03-04 Trustees Of The University Of Pennsylvania, The Center For Technology Transfer Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
WO2000023457A1 (en) 1998-10-16 2000-04-27 Pfizer Limited Adenine derivatives
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
DE60006116T2 (de) 1999-06-22 2004-07-08 CV Therapeutics, Inc., Palo Alto A2a rezeptor agonisten
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
WO2002009702A2 (en) 2000-07-28 2002-02-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
IL156704A0 (en) 2001-01-16 2004-01-04 Can Fite Biopharma Ltd Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
EP1423175B1 (en) 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
ATE418991T1 (de) 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
CN1650001A (zh) 2002-04-30 2005-08-03 爱尔康公司 作为降低眼内压和治疗青光眼性视网膜病变 /眼神经病的独特手段的调控、抑制或调节结缔组织生长因子( ctgf)的活性和／或表达的药物
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004056181A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery (2)
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
CA2554716A1 (en) 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
ME01072B (me) 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
CN1980946A (zh) 2004-07-12 2007-06-13 Cv医药有限公司 用于制备a1腺苷受体激动剂的方法
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
BRPI0619261A2 (pt) 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
EP2407171A3 (en) 2006-02-02 2012-04-11 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20070238694A1 (en) 2006-03-23 2007-10-11 Inotek Pharmaceuticals Corporation Purine compounds and methods of use thereof
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
JP2010505848A (ja) * 2006-10-06 2010-02-25 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧を低下させるための種交差性ａ３アデノシン受容体アンタゴニストの効果的送達
PL2083629T5 (pl) 2006-11-10 2016-03-31 Basf Se Krystaliczna odmiana fipronilu
AU2007327990A1 (en) 2006-12-05 2008-06-12 The Royal Institution For The Advancement Of Learning/ Mcgill University Methods of use of TRK receptor modulators
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
JP5674469B2 (ja) 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
EP2259790A1 (en) 2008-02-07 2010-12-15 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof
WO2010056981A2 (en) 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
EP2424546B1 (en) 2009-05-01 2015-10-28 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
EA201200635A1 (ru) * 2009-10-26 2012-10-30 Инотек Фармасьютикалз Корпорейшн Глазной состав и способ его изготовления
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
ES2613698T3 (es) 2010-01-11 2017-05-25 Inotek Pharmaceuticals Corporation Combinación, kit y método de reducción de la presión intraocular
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
PT2555776T (pt) 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
SG184221A1 (en) * 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
EA201290959A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Соединения аденозина и их применения
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
KR20140128974A (ko) 2012-01-26 2014-11-06 이노텍 파마슈티컬스 코포레이션 ((2r,3s,4r,5r)-5-(6-(시클로펜틸아미노)-9h-퓨린-9-일)-3,4-디히드록시테트라히드로푸란-2-일) 메틸 니트레이트의 무수 다형체들 및 이들의 제조 방법들
MX2015013240A (es) 2013-03-15 2016-04-07 Inotek Pharmaceuticals Corp Método para proporcionar neuroprotección ocular.
NZ630759A (en) * 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist

Also Published As

Publication number Publication date
ZA201207090B (en) 2014-03-26
US8476247B2 (en) 2013-07-02
SG184221A1 (en) 2012-10-30
US20140018314A1 (en) 2014-01-16
AU2011230580A1 (en) 2012-10-11
BR112012023749A2 (pt) 2016-08-23
US20150080330A1 (en) 2015-03-19
WO2011119969A1 (en) 2011-09-29
KR20130029050A (ko) 2013-03-21
US9289383B2 (en) 2016-03-22
CA2792266A1 (en) 2011-09-29
JP2016147918A (ja) 2016-08-18
US20160158268A1 (en) 2016-06-09
US20110245195A1 (en) 2011-10-06
EP2569325A4 (en) 2013-10-09
JP2013523739A (ja) 2013-06-17
MX2012010724A (es) 2012-11-12
CL2012002613A1 (es) 2012-12-21
EP2569325A1 (en) 2013-03-20
CN102933593A (zh) 2013-02-13
EA201290958A1 (ru) 2013-04-30
US8895530B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
CO6630141A2 (es) Método para reducir la presión intraocular en sere humanos empleando n6-ciclopentiladenosina (cpa) derivados de cpa o profármacos de estos
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
AR103130A1 (es) Sonda de vitrectomía con un escáner de fibra óptica
AR097661A1 (es) Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO7151524A2 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciación y usos de los mismos
CY1118384T1 (el) Μια συσκευη οφθαλμικης χειρουργικης επεμβασης
PL412337A1 (pl) Wziernik nosowy
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
BR112015007549A2 (pt) produto de argila e seus usos
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
GT200600277A (es) Derivados de prostaglandina
MX2020004730A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
WO2010141586A3 (en) Therapeutic ophthalmic emulsions
EA201290959A1 (ru) Соединения аденозина и их применения
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
UY33153A (es) Formulación tópica oftálmica de péptidos
CL2016000220A1 (es) Un dispositivo adaptable a grapadoras quirúrgicas, útil para cirugías de gastrectomía en manga o gastrectomía total.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.

Legal Events

Date Code Title Description
FC Application refused